Literature DB >> 31098699

[New drugs for treatment of juvenile idiopathic arthritis].

Gerd Horneff1.   

Abstract

The introduction of biologics 20 years ago has significantly changed the pharmacotherapy of juvenile idiopathic arthritis. Biologics are among the most successful innovations, not only in rheumatology. In addition to their strong efficacy the rapid onset of improvement , biologics offer an option for prevention of long-term damage and a realistic prospect of remission. This article discusses innovations in biologics and the importance of the latest group for targeted therapy with small molecules in pediatric rheumatology.

Entities:  

Keywords:  Antirheumatic agents; Interleukin receptors; Janus kinase inhibitors; Molecular targeted therapy; Tumor necrosis factor

Mesh：

Substances：

Year:  2019        PMID： 31098699     DOI： 10.1007/s00393-019-0646-3

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


  42 in total

1.  Risk of Serious Infection in Juvenile Idiopathic Arthritis Patients Associated With Tumor Necrosis Factor Inhibitors and Disease Activity in the German Biologics in Pediatric Rheumatology Registry.

Authors:  Ingrid Becker; Gerd Horneff
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-04       Impact factor: 4.794

2.  A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.

Authors:  K A Papp; K Reich; C Paul; A Blauvelt; W Baran; C Bolduc; D Toth; R G Langley; J Cather; A B Gottlieb; D Thaçi; J G Krueger; C B Russell; C E Milmont; J Li; P A Klekotka; G Kricorian; A Nirula
Journal:  Br J Dermatol       Date:  2016-06-23       Impact factor: 9.302

3.  Update on malignancies in children with juvenile idiopathic arthritis in the German BIKER Registry.

Authors:  Gerd Horneff; Ariane Klein; Prasad T Oommen; Anton Hospach; Ivan Foeldvari; Isa Feddersen; Kirsten Minden
Journal:  Clin Exp Rheumatol       Date:  2016-09-08       Impact factor: 4.473

4.  Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis.

Authors:  Esi Morgan DeWitt; Yukiko Kimura; Timothy Beukelman; Peter A Nigrovic; Karen Onel; Sampath Prahalad; Rayfel Schneider; Matthew L Stoll; Sheila Angeles-Han; Diana Milojevic; Kenneth N Schikler; Richard K Vehe; Jennifer E Weiss; Pamela Weiss; Norman T Ilowite; Carol A Wallace
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-07       Impact factor: 4.794

5.  A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population.

Authors:  Alan J Kivitz; Stanley Cohen; Edward Keystone; Ronald F van Vollenhoven; Boulos Haraoui; Jeffrey Kaine; Haiyun Fan; Carol A Connell; Eustratios Bananis; Liza Takiya; Roy Fleischmann
Journal:  Semin Arthritis Rheum       Date:  2018-07-19       Impact factor: 5.532

6.  Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.

Authors:  Fabrizio De Benedetti; Hermine I Brunner; Nicolino Ruperto; Andrew Kenwright; Stephen Wright; Inmaculada Calvo; Ruben Cuttica; Angelo Ravelli; Rayfel Schneider; Patricia Woo; Carine Wouters; Ricardo Xavier; Lawrence Zemel; Eileen Baildam; Ruben Burgos-Vargas; Pavla Dolezalova; Stella M Garay; Rosa Merino; Rik Joos; Alexei Grom; Nico Wulffraat; Zbigniew Zuber; Francesco Zulian; Daniel Lovell; Alberto Martini
Journal:  N Engl J Med       Date:  2012-12-20       Impact factor: 91.245

7.  Biologic effects of an interleukin-1 receptor antagonist protein on interleukin-1-stimulated cartilage erosion and chondrocyte responsiveness.

Authors:  R J Smith; J E Chin; L M Sam; J M Justen
Journal:  Arthritis Rheum       Date:  1991-01

8.  Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study.

Authors:  Nicolino Ruperto; Hermine I Brunner; Zbigniew Zuber; Nikolay Tzaribachev; Daniel J Kingsbury; Ivan Foeldvari; Gerd Horneff; Elzbieta Smolewska; Richard K Vehe; Anasuya Hazra; Rong Wang; Charles A Mebus; Christine Alvey; Manisha Lamba; Sriram Krishnaswami; Thomas C Stock; Min Wang; Ricardo Suehiro; Alberto Martini; Daniel J Lovell
Journal:  Pediatr Rheumatol Online J       Date:  2017-12-28       Impact factor: 3.054

Review 9.  Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature.

Authors:  Devis Benfaremo; Lucia Manfredi; Michele Maria Luchetti; Armando Gabrielli
Journal:  Curr Drug Saf       Date:  2018

10.  Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial.

Authors:  Alvin F Wells; Christopher J Edwards; Alan J Kivitz; Paul Bird; Dianne Nguyen; Maria Paris; Lichen Teng; Jacob A Aelion
Journal:  Rheumatology (Oxford)       Date:  2018-07-01       Impact factor: 7.580
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.